[HTML][HTML] Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

SJ Hotte, A Oza, EW Winquist, M Moore, EX Chen… - Annals of oncology, 2006 - Elsevier
Abstract Background: 7-Hydroxystaurosporine (UCN-01) inhibits serine–threonine kinases
including the Ca 2+ and phospholipid-dependent protein kinase C (PKC), CDKs 2, 4, 6, Chk …

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.

SJ Hotte, A Oza, EW Winquist, M Moore… - Annals of Oncology …, 2005 - europepmc.org
Background 7-Hydroxystaurosporine (UCN-01) inhibits serine-threonine kinases including
the Ca2+ and phospholipid-dependent protein kinase C (PKC), CDKs 2, 4, 6, Chk-1 and …

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

SJ Hotte, A Oza, EW Winquist, M Moore… - Annals of …, 2006 - annalsofoncology.org
Abstract Background: 7-Hydroxystaurosporine (UCN-01) inhibits serine–threonine kinases
including the Ca 2+ and phospholipid-dependent protein kinase C (PKC), CDKs 2, 4, 6, Chk …

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

SJ Hotte, A Oza, EW Winquist… - Annals of oncology …, 2006 - pubmed.ncbi.nlm.nih.gov
Background 7-Hydroxystaurosporine (UCN-01) inhibits serine-threonine kinases including
the Ca2+ and phospholipid-dependent protein kinase C (PKC), CDKs 2, 4, 6, Chk-1 and …

[引用][C] Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

SJ Hotte, A Oza, EW Winquist, M Moore, EX Chen… - Annals of …, 2006 - cir.nii.ac.jp
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid
cancers: a Princess Margaret Hospital Phase II Consortium study | CiNii Research CiNii 国立 …

[PDF][PDF] Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

SJ Hotte, A Oza, EW Winquist, M Moore… - Annals of …, 2006 - researchgate.net
Background: 7-Hydroxystaurosporine (UCN-01) inhibits serine–threonine kinases including
the Ca2+ and phospholipid-dependent protein kinase C (PKC), CDKs 2, 4, 6, Chk-1 and …

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

SJ Hotte, A Oza, EW Winquist, M Moore, EX Chen… - Annals of …, 2006 - elibrary.ru
Background: 7-Hydroxystaurosporine (UCN-01) inhibits serine–threonine kinases including
the Ca2+ and phospholipid-dependent protein kinase C (PKC), CDKs 2, 4, 6, Chk-1 and …

[引用][C] Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

SJ HOTTE, A OZA, EW WINQUIST… - Annals of …, 2006 - pascal-francis.inist.fr
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers :
a Princess Margaret Hospital Phase II Consortium study CNRS Inist Pascal-Francis CNRS …

[PDF][PDF] Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

SJ Hotte, A Oza, EW Winquist, M Moore… - Annals of …, 2006 - researchgate.net
Background: 7-Hydroxystaurosporine (UCN-01) inhibits serine–threonine kinases including
the Ca2+ and phospholipid-dependent protein kinase C (PKC), CDKs 2, 4, 6, Chk-1 and …

[引用][C] Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

SJ HOTTE, A OZA, EW WINQUIST… - Annals of …, 2006 - Oxford University Press